Zimmer Biomet Holdings, Inc.

ZBH Healthcare Medical Devices

Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024.

Revenue
+3.07%
EPS
−13.5%
Free cash flow
+29.8%
Total debt
−7.50%

Quarter to September 2026, against a year earlier

105.28 1.57 −1.47%
Market cap
$20.4B
P/E
26.5×
Fwd P/E
18.9×
Dividend yield
0.91%
F-score
6/9
Altman Z
2.38
Beneish M
−2.59
Dividend safety
72/100

Zimmer Biomet Holdings, Inc. 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:06 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 1, 2026: 3 added · 1 removed · 28 modified; 5 with only figures updated

  1. Added

    The Paragon 28 acquisition was completed on April 21, 2025. The Paragon 28 impacts on year-over-year net sales growth in the following discussion and analysis refer to net sales of Paragon 28 products from January 1, 2026 through the one-year anniversary in April 2026, since there are no prior year comparable net sales of those products for the time period.